Amgen's (AMGN) Aranesp "145 Study'' Shows No Difference in Survival in Patients with Small-Cell Lung Cancer
More News related to AMGN
- Stelara is Expected to Substantially Alter Patient Flow to TNF-Alpha Inhibitors Prescribed for Psoriasis Over the Next Two Years
- Amgen (AMGN) Announces Cancer Survival Results when Faced with Vectibix in Combination with FOLFOX
- Amgen Announces Overall Survival Results for Vectibix(R) in First-Line Metastatic Colorectal Cancer
- Call for Applications: The Amgen Award for Science Teaching Excellence
- Trading Outlook for Avanir Pharmaceuticals Inc. Issued by InvestorSoup.com
More News related to FDA
- Kensey Nash (KNSY) Receives FDA Clearance for its First Extracellular Matrix Product, Medeor
- Teva Pharma (TEVA) Gets Final U.S. FDA Approval for Generic Prevacid
- Mylan (MYL) Gets FDA Ok for Generic Prevacid
Amgen (NASDAQ: AMGN) announced the results of the "145 study", a randomized, double-blind, placebo-controlled, multicenter Phase 3 study of Aranesp® (darbepoetin alfa) in 600 previously untreated patients with extensive-stage small-cell lung cancer (SCLC) receiving platinum-containing chemotherapy. The study demonstrated no statistically significant difference in risk of death.
The study demonstrated a significant change in hemoglobin concentration from baseline in favor of Aranesp (a co-primary endpoint). Aranesp-treated patients also experienced a significantly lower risk of blood transfusions (HR: 0.40, 95% CI: 0.29 to 0.55). The overall safety profile, including thromboembolic events, was consistent with that described in the U.S. label.
Related Categories
FDAStocks Mentioned
+0.70Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
